Alerta

BIOMARKERS FOR THE ASSESSMENT OF POST-HEMORRHAGIC STROKE

Resumen de: WO2026076444A1

Methods of measuring the effects of an intracerebral hemorrhage are disclosed herein and include: acquiring at least one blood, serum, or plasma sample from a patient suffering from intracerebral hemorrhage, utilizing the at least one blood, serum, or plasma sample to isolate at least one neuron-derived extracellular vesicle, at least one oligodendrocyte-derived extracellular vesicle, at least one astrocyte-derived extracellular vesicle, or a combination thereof to form an extracellular vesicle isolate composition, analyzing the exosome isolate composition to identify at least one surface associated biomarker, wherein the at least one surface biomarker is located on the surface of the at least one neuron-derived extracellular vesicle, at least one oligodendrocyte-derived extracellular vesicle, the at least one astrocyte-derived extracellular vesicle, or the combination thereof, and quantifying the at least one surface biomarker to monitor post-hemorrhage cellular and molecular cascades in the patient.

CUSTOM PRINTED STRUCTURES FOR CELL GROWTH AND MOTILITY ASSAYS

Resumen de: WO2026076275A1

Disclosed herein are systems and methods for measuring cell growth and movement. The methods can include synthesizing custom obstacle courses around individual cells or cell aggregates, and measuring their movement and/or growth through the obstacle course. The cells and cell aggregates can be subjected to further analyses to correlate phenotypic and genotypic traits with the movement and/or growth.

DIAGNOSTIC METHODS FOR AMYLOIDOSIS AND RELATED DISORDERS

Resumen de: WO2026075851A1

The present invention provides novel non-invasive methods for detecting misfolded transthyretin (TTR) proteins, and for diagnosing and monitoring amyloidosis and related disorders.

SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Resumen de: WO2026076209A1

The present invention relates to the systems and methods of identifying compounds to treat or prevent chronic obstructive pulmonary disorders (COPD). The present invention also provides compositions to treat or prevent COPD comprising modulators of one or more selected from the group consisting of: AC AN, ACTN1, ADAMTS4, ADRB2, AGER, AN06, AP3B1, AP0A1, ARRB1, ATP1A1, BCL2L1, BDKRB1, BRAF, CALCRL, CCL11, CDH1, CEACAM8, CHRM3, CHRNA1, CLU, COL10A1, COL12A1, COL14A1, COL4A2, COL6A1, COL6A3, COLGATE 1, CRH, CSK, CTSD, CTTN, CXCR1, CXCR4, CXCR5, FBN1, FGA, FGG, FHL2, FTH1, GNB1, GPIHBP1, GPR84, GPR97, GRM8, HAPLN1, H2BFS, HBB, HSP90B1, ICAM1, IGF1R, IL6, ITGA1, ITGAV, LAMA2, LAMA4, LRP1, LTBP1, MAPK3, MGAM, MMP1, MMP13, MMP3, MMP9, MYBPH, MYH10, MYH9, NMU, NR3C1, P4HB, PLCB3, PLAG2G7, POU2AF1, PPIB, PROK2, RUNX2, RXFP1, S100A12, S100P, SAA1, SDC2, SLC2A5, SMAD3, SPARCL1, SPP1, SYT13, TBX1, TF, TGFB2, THBS1, TIMP1, TLN1, TPM1, TPM2, TPM4, TSPAN14, TEN, TWIST2, VIM, and WT1, and methods of use thereof.

METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN

Resumen de: US20260097094A1

0000 Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF

Resumen de: US20260098080A1

0000 A protein comprising amino acid sequence of SEQ ID NO: 115, within which a segment of general formula Ih-mod GX<1>CX<1V>X<2>X<3>X<4>X<5 >is present where X<1 >is any of F, Y, L, P, Q, M, V, W, A, or T, X<1V >is R, or K, X<2 >is any of A, G, S, or T, X<3 >is any amino acid of the 17-set, where the 17-set comprises A, I, L, F, or Y, X<4 >is any of K, I, Q, R, H, S, F, M, N, L, or V, and X<5 >is any of R, V, I, K, M, Q, E, F, L, N, Y, D, S, H; and b) in position 34 of SEQ ID NO: 115 it contains an amino acid selected from the 34-set contains any amino acid of the 34-set, where the 34-set comprises Y, I, F, G, V and S, and use in pharmaceutical preparations, kits, screening procedures.

NON-INVASIVE METHOD FOR DETERMINING RESPIRATORY GASES COMPRISING HYDROGEN SULPHIDE

Resumen de: EP4721657A1

Die vorliegende Erfindung betrifft ein nicht-invasives Verfahren zur Bestimmung von Atemgasen aufweisend Schwefelwasserstoff, insbesondere zur Verwendung in der Medizin, Diagnose, Prädiktion, Risikostratifizierung und Therapiesteuerung von Erkrankungen, insbesondere Darmerkrankungen an Probanden, wobei durch Bakterien gebildete Gase in dem Ausatemgas bestimmt werden, wobei der Schwefelwasserstoff nicht nachteilig abgebaut wird.

预防和治疗阿尔茨海默病药物、靶点、药物筛选方法

Resumen de: CN121796373A

本发明属于生物医药领域，具体的，本发明涉及了预防和治疗阿尔茨海默病药物、靶点、药物筛选方法。本发明揭示了甲状腺激素T4在治疗神经病变中核心靶标蛋白碘化PP2A的作用，为开发预防和治疗神经退行相关疾病的新药物、监测相关药物治疗效果提供了技术基础。甲状腺激素T4可以作为改善受试者记忆与认知功能的药物；补充甲状腺激素T4还可以用于预防和治疗神经退行性相关疾病，为甲状腺激素T4提供了一种全新的医药用途。

一种复合蛋白及其制备方法和应用

Resumen de: CN121800903A

本发明公开了一种复合蛋白及其制备方法和应用，涉及生物领域。本发明开发了一种多磷酸化tau复合蛋白，其包括链霉亲和素以及与所述链霉亲和素相连的抗原A‑生物素A和抗原B‑生物素B，解决现有校准品与天然抗原表位的差异引发试剂批间差过大的问题，校准性能突破性提升，可适配化学发光、酶联免疫等多种检测平台，通用性强，具有重要的临床价值与行业意义。

一种基于RT-QuIC技术的帕金森病辅助诊断试剂盒及其应用

Resumen de: CN121805593A

0001 本发明提供一种基于RT‑QuIC技术的帕金森病辅助诊断试剂盒及其应用，属于检测试剂盒技术领域。本发明提供的试剂盒具有显著的微创性与高患者依从性，仅需采集微量皮肤组织即可完成检测，避免了腰椎穿刺或脑组织活检的风险与痛苦。该试剂盒检测性能优异，能够实现对帕金森病早期病理的高度敏感与特异的识别，且检测流程快捷，可在较短时间内完成批量样本分析，有力支持临床的快速诊断与筛查需求。同时，其整体成本显著低于影像学等现有方法，为帕金森病的早期发现、临床辅助诊断及治疗效果观察提供了便捷、可靠且经济的分子检测手段，对提升该类神经退行性疾病的整体诊疗水平具有积极意义。

基于氮化硅纳米孔和深度学习的生物标志蛋白检测系统

Resumen de: CN121805567A

0001 本发明公开了基于氮化硅纳米孔和深度学习的生物标志蛋白检测系统，涉及纳米孔蛋白检测技术领域，包括基于电导‑孔径公式计算实现孔径的控制；保留并表征结构蛋白在过孔过程中产生的电信号差异；完成生物标志蛋白检测。本发明实现了对结构高度相似的β‑淀粉样蛋白40与β‑淀粉样蛋白42的高精度、高稳定性区分；提升了分类准确率，整体方案兼具工艺可控性、信号解析深度与模型识别能力，为阿尔茨海默病等神经退行性疾病的早期诊断提供了可靠、可产业化的单分子检测技术路径。

用于主动脉夹层检测的生物标志物及其应用

Resumen de: CN121802031A

0001 本发明公开了用于主动脉夹层检测的生物标志物及其应用，所述生物标志物为MDK、NTN1、CCL21、LIPC、DNASE1L3、TFPI2、CTSG、HAMP、CXCL14、PLA2G2A、SCUBE1、GZMK、HP1BP3、SRP14、TOP1中的一种或多种。所述生物标志物通过血浆蛋白组学对主动脉夹层患者血浆筛选而出，表现出较高的敏感性和特异性。本发明通过ELISA验证证明了所述生物标志物可作为主动脉夹层早期诊断性生物标志物，还可以作为评估AD患者疾病严重程度的指标之一，这为主动脉夹层临床早期诊断和远期预后评估，提供了新的方向。

检测MAPT蛋白S202和T205位点磷酸化水平的试剂在制备肾脏纤维化诊断产品中的应用

Resumen de: CN121805597A

0001 本发明公开检测MAPT蛋白S202和T205位点磷酸化水平的试剂在制备肾脏纤维化诊断产品中的应用，本发明首次将MAPT蛋白的功能研究从传统的肾小球足细胞领域拓展至肾小管上皮细胞及其纤维化病理过程，开辟了MAPT蛋白在肾脏疾病研究中的全新方向。不同于既往仅依赖整体基因敲除或过表达的笼统性研究手段，本发明利用位点特异性突变体实现了对MAPT关键磷酸化位点功能的精准解析。通过系统性功能判定实验，本发明揭示了一项具有重大理论意义的反直觉生物学规律：尽管S202和T205位点磷酸化显著驱动肾小管上皮细胞纤维化进程，但模拟该位点去磷酸化状态（S202A/T205A突变体）却无法改善纤维化表型。

AAV METHODS OF AAV THERAPY

Resumen de: WO2019246237A1

This disclosure provides methods for identifying a subject suitable for an adeno associated virus (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV ("anti-AAV antibody") in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).

ＹａｘＡＢナノポア、それを含むナノポアシステム、およびその活用

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

分析物を検出するための方法

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

基于APOE-ε2蛋白的阿尔兹海默症检测产品及其应用

Resumen de: CN121784304A

0001 本发明公开了一种标志物在制备阿尔兹海默症的检测产品中的用途，其中，标志物为APOEε2蛋白；检测产品为试剂盒，用于评估阿尔兹海默症疾病进展或严重程度；检测产品所检测的样品为受试者的外周血样本或脑脊液。本发明还提供了一种相应的检测试剂盒，其包含能够特异性结合APOEε2蛋白的结合分子。此外，本发明提供了一种体外非诊断性检测方法，包括使用所述试剂盒检测样本中APOEε2蛋白的浓度，并可对同一受试者的系列样本进行检测以获得浓度动态变化数据。本发明突破了将APOEε2仅作为静态遗传风险因子的传统认知，首次将其外周体液中的蛋白浓度动态变化确立为与AD疾病活动相关的客观量化指标，为AD的疾病进程研究及长期随访管理提供了重要的工具与数据支持。

检测抗GLUL自身抗体的试剂在诊断神经系统自身免疫性疾病中的应用

Resumen de: CN121784288A

0001 本发明公开了检测抗GLUL自身抗体的试剂在诊断神经系统自身免疫性疾病中的应用，属于蛋白诊断试剂制备技术领域。本发明通过对比具有神经系统自身免疫性疾病症状的患者血清和健康人血清，得到以下结果：相比健康人血清，具有神经系统自身免疫性疾病症状的患者血清中存在抗GLUL自身抗体，通过大量的实验进行验证，明确抗GLUL自身抗体可作为诊断神经系统自身免疫性疾病的标志物，尤其是作为辅助诊断神经系统自身免疫性疾病的抗神经细胞抗体。检测抗GLUL自身抗体能够实现神经系统自身免疫性疾病的诊断，尤其是能实现自身免疫性脑炎的辅助诊断。

抗LRP4抗体及其应用

Resumen de: CN121779562A

本发明公开了一种抗LRP4抗体及其应用。其具有依次如SEQ ID NO：2‑4所示的重链CDR1‑3和依次如SEQ ID NO：6‑8所示的轻链CDR1‑3。本发明中的抗LRP4抗体可以有效用于细胞或者组织样本LRP4抗原检测（如免疫荧光检测）或免疫印迹分析，而且能够作为抗LRP4抗体检测试剂盒的阳性标品，直接使用同一套抗人的荧光二抗，简化了检测试剂盒的成分组成。

一种用于诊断阿尔茨海默症的血液星形胶质细胞衍生外泌体标志物及组合

Resumen de: CN121780683A

0001 本发明提供了一种用于诊断阿尔茨海默症的血液星形胶质细胞衍生外泌体标志物及组合。具体地，本发明提供了在血浆中星形胶质细胞衍生的外泌体内的关键核酸标志物（包括SET、GADME、ADAMTSL3、CP等）。相较于外周血中的经典蛋白标志物，这些核酸标志物在体内更稳定不易被降解。使得仅通过采血检测便能检测AD患者脑内的病理状态变化成为可能。并且与传统的蛋白标志物检测方法相比，本发明中的核酸标志物仅通过RT‑qPCR即可完成检测，检测平台具有普适性操作简单且检测成本低。

线粒体Rab32在制备用于治疗慢性睡眠剥夺药物中的应用及其研究方法

Resumen de: CN121775117A

0001 本发明公开了线粒体Rab32在制备用于治疗慢性睡眠剥夺药物中的应用及其研究方法，属于生物医药技术领域。本发明通过建立慢性睡眠剥夺小鼠模型，研究线粒体Rab32与SD小鼠体内蛋白变化的关系，结果表明，线粒体Rab32通过锚定细胞内Sptan1，参与细胞骨架蛋白功能调控，参与神经元的突触再生，由此可得，Rab32是介导SD小鼠神经元突触再生、调节突触可塑性和认知功能障碍的关键分子，该研究结果可能为今后SD相关认知功能障碍的治疗提供新的靶点。

SEMA3G抗原结合蛋白及其用途

Resumen de: CN121779558A

0001 本申请涉及生物医药领域，具体涉及SEMA3G抗原结合蛋白及其用途。本申请提供一种分离的抗原结合蛋白，所述抗原结合蛋白结合SEMA3G蛋白，所述抗原结合蛋白包括重链可变区和轻链可变区；所述重链可变区包括如SEQ ID NO.3、11、19任一项所示的HCDR1，如SEQ ID NO.4、12、20任一项所示的HCDR2，如SEQ ID NO.5、13、21任一项所示的HCDR3；所述轻链可变区包括如SEQ ID NO.6、14、22任一项所示的LCDR1，如SEQ ID NO.7、15、23任一项所示的LCDR2，如SEQ ID NO.8、16、24任一项所示的LCDR3；本申请的抗原结合蛋白能够以高亲和力结合上述靶蛋白并且中和其对T细胞功能的抑制活性，从而达到解除肿瘤细胞免疫逃逸功能的作用，促进免疫细胞在体内外对肿瘤细胞的杀伤，可用于制备调节免疫反应或具有抗肿瘤作用的药物。

DEVICE, METHOD AND SYSTEM FOR BIOMARKER DETECTION

Resumen de: WO2026073292A2

A point-of-care device and method for simultaneously and quantitatively assessing a magnetically-labelled analyte immobilised on a lateral flow test strip are provided. The method comprises the steps of sensing a magnetic signal from the magnetically-labelled analyte on the test strip and converting the magnetic signal into an electric signal; processing the electric signal to obtain a quantitative value of the amount of analyte; and processing the values to provide a differential assessment between the magnetically-labelled analyte. The device includes a magnetic reader with at least one magnetic sensor, such as a giant magnetoresistive sensor. The magnetic sensor can be directly or indirectly coupled to a lock-in amplifier configured to perform phase-sensitive detection and enhance the signal-to-noise ratio of weak magnetic signals. A system, microfluidics device, lateral flow immunoassay test strip and kit are also provided.

METHODS FOR BIOMARKER IDENTIFICATION FOR DIAGNOSIS OF NEUROPSYCHIATRIC DISORDERS

Resumen de: WO2026072844A1

Schizophrenia (SCZ) is the most debilitating of the Serious Mental Illnesses, a group of disorders affecting 4.8% of Arizona adults. The lack of a biologically based test makes diagnosing SCZ difficult, particularly for the 40% of Arizonans in areas with inadequate mental health care. Even under ideal circumstances, it can take months to years to accurately diagnose SCZ and identify an effective medication regimen. There is a critical need to identify biological markers to rapidly diagnose SCZ, which will lead to faster symptom resolution and improved patient outcomes. Methods described herein capitalize on the long-recognized association between SCZ risk and immune system dysfunction by stimulating peripheral blood immune cells with immunogenic agents to gain insight into disrupted pathways of gene expression in the brain. The immune stimulation of peripheral blood cells produces a unique pattern of gene expression, which will differ between SCZ and healthy control subjects.

SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF

Nº publicación: US20260091079A1 02/04/2026

Solicitante:

CHILDRENS MEDICAL CENTER [US]

Resumen de: US20260091079A1

0000 Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.